Related Experiment Video
Updated: Jul 24, 2025
Tumor Hypoxia Assessment: In Vivo 3D Oxygen Imaging Through Electron Paramagnetic Resonance
Published on: February 14, 2025
Molecular imaging of tumor hypoxia: Evolution of nitroimidazole radiopharmaceuticals and insights for future
Sweety Mittal1, Madhava B Mallia2
1Radiopharmaceuticals Division, Bhabha Atomic Research Center, Mumbai 400085, India.
Abstract:
Though growing evidence has been collected in support of the concept of dose escalation based on the molecular level images indicating hypoxic tumor sub-volumes that could be radio-resistant, validation of the concept is still a work in progress. Molecular imaging of tumor hypoxia using radiopharmaceuticals is expected to provide the required input to plan dose escalation through Image Guided Radiation Therapy (IGRT) to kill/control the radio-resistant hypoxic tumor cells. The success of the IGRT, therefore, is heavily dependent on the quality of images obtained using the radiopharmaceutical and the extent to which the image represents the true hypoxic status of the tumor in spite of the heterogeneous nature of tumor hypoxia. Available literature on radiopharmaceuticals for imaging hypoxia is highly skewed in favor of nitroimidazole as the pharmacophore given their ability to undergo oxygen dependent reduction in hypoxic cells. In this context, present review on nitroimidazole radiopharmaceuticals would be immensely helpful to the researchers to obtain a birds-eye view on what has been achieved so far and what can be tried differently to obtain a better hypoxia imaging agent. The review also covers various methods of radiolabeling that could be utilized for developing radiotracers for hypoxia targeting applications.
Insights
Molecular imaging of tumor hypoxia using radiopharmaceuticals can guide radiation therapy dose escalation. This review focuses on nitroimidazole agents for better imaging of radio-resistant hypoxic tumor cells.
Area of Science:
- Oncology
- Radiochemistry
- Medical Imaging
Background:
- Tumor hypoxia is linked to radio-resistance, necessitating targeted therapies.
- Molecular imaging of tumor hypoxia is crucial for image-guided radiation therapy (IGRT) dose escalation.
- Accurate imaging of heterogeneous tumor hypoxia is essential for effective IGRT.
Purpose of the Study:
- To review nitroimidazole-based radiopharmaceuticals for imaging tumor hypoxia.
- To provide an overview of current achievements and future directions in hypoxia imaging agents.
- To explore radiolabeling methods for developing novel hypoxia-targeting radiotracers.
Main Methods:
- Literature review of nitroimidazole radiopharmaceuticals for hypoxia imaging.
- Analysis of radiolabeling techniques for hypoxia-targeting applications.
Main Results:
- Nitroimidazoles are the predominant pharmacophore for hypoxia imaging due to their oxygen-dependent reduction.
- The review synthesizes existing knowledge on hypoxia imaging agents.
- Various radiolabeling strategies are discussed for developing improved radiotracers.
Conclusions:
- Nitroimidazole radiopharmaceuticals are vital for molecular imaging of tumor hypoxia.
- Further research into novel agents and radiolabeling methods is needed for enhanced hypoxia detection.
- Improved hypoxia imaging agents will support more effective image-guided radiation therapy for radio-resistant tumors.
Related Concept Videos
01:13Radiological Investigation III: Pulmonary Angiogram and PET Scan
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
01:25Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET